Class/mechanism: Superparamagnetic iron oxide that is coated with a carbohydrate shell, which isolates the iron from plasma components until the iron-carbohydrate complex enters the reticuloendothelial system macrophages of the liver, spleen, and bone marrow. Iron is released from the iron-carbohydrate complex within vesicles in the macrophages.
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Patient drug information
- Ferumoxytol (Feraheme) patient drug information (AMAG Pharmaceuticals)
- Ferumoxytol (Feraheme) patient drug information (UpToDate)
History of changes in FDA indication
- 6/30/2009: Initial FDA approval "for the treatment of iron deficiency anemia in adult patients with chronic kidney disease (CKD)."
Also known as
- Brand name: Feraheme